1Zeuzeml S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol, 2009, In press.
3Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int, 2008, 2: 263-283.
2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
3DiBisceglie A,Lai CL,Gane E. Telbivudine GLOBE trial:Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients[J].Hepatology,2006,(01):230-231.